The survey of 3,488 U.S. adults — conducted between June 22 and June 28 — found that nearly three-quarters of respondents said it is extremely or very important that doctors and other healthcare providers disclose when artificial intelligence is being used in their care. A further four in five said patients should be informed specifically when AI is used to analyze medical scans, make diagnoses, or explain laboratory results.

A Clear and Consistent Demand for Transparency

The demand for AI disclosure healthcare was notably consistent across demographic groups. Majorities across age, gender, education, and racial and ethnic backgrounds agreed that disclosure was extremely or very important. Adults aged 65 and older were somewhat more likely to prioritize disclosure compared to those under 30, but the overall consensus remained strong across all groups surveyed.

Transparency expectations extended beyond high-stakes clinical decisions. According to the Pew findings, 72% of respondents said providers should disclose when AI takes notes during an appointment, 64% said disclosure is warranted when AI orders prescription refills, and 56% said they want to be informed even when the technology is used for appointment scheduling.

Patients Report Limited Awareness and Control

Despite the broad appetite for transparency, the survey found a considerable gap between patient expectations and their actual experiences. Nearly half of all respondents — 46% — said they were not sure whether a provider had already used AI in their healthcare. Among those who reported having encountered AI in a clinical setting, only 22% said they understood extremely or very well how the technology had been used.

The sense of limited control was equally striking. Just 17% of adults said they have a great deal or quite a bit of control over whether providers use AI in their health care. A further 53% said they feel they have little or no say in the matter.

AI Adoption Among Providers Continues to Accelerate

The findings arrive at a time when artificial intelligence in healthcare is being adopted at a rapid pace. According to data from the Office of the National Coordinator, 71% of non-federal acute care hospitals reported using predictive AI in 2024, up from 66% the year prior. The fastest-growing applications included billing and scheduling functions.

Physician adoption has followed a similar upward trajectory. An American Medical Association survey conducted earlier this year found that 72% of physician respondents had incorporated at least one AI application into their practice — nearly double the share reported in 2023. Documentation and summarization tools were cited among the most common uses.

Echoes of Earlier Concerns

The latest Pew data revisits concerns the research organization had identified even before the current wave of AI adoption in clinical settings. In 2023, 60% of Americans said they would be uncomfortable if their provider relied on AI to diagnose conditions or recommend treatments. Three-quarters of respondents at that time were more concerned that providers would implement the technology too quickly than too slowly.

The current survey reinforces that those concerns have not dissipated — and in some respects, the gap between AI disclosure healthcare expectations and actual practice has widened alongside accelerating adoption across hospitals and physician practices alike.

These FDA clearances support the company’s efforts to help clinical laboratories transition beyond basic digitization into fully connected, standardized, and scalable diagnostic workflows. The updated portfolio introduces Aperio iQC DX software, adds the Aperio GT 180 DX scanner, and incorporates enhanced features for the Aperio GT 450 DX scanner.

AI-Assisted Quality Control Software for Clinical Workflows

The newly cleared Aperio iQC DX software is the industry’s first FDA 510(k)-cleared quality control software designed for AI-assisted digital pathology in a clinical environment. Whole slide images are frequently subject to quality issues caused during tissue preparation, staining, coverslipping, or scanning. These issues include air bubbles, pen marks, clipped tissue, missing tissue, out-of-focus regions, and image striping.

By automatically detecting these six common slide artifacts while slides remain on the scanner, the software allows laboratories to recognize and resolve potential quality issues earlier in the process. This automated capability reduces the necessity for rescanning or rework, limits downstream delays, and promotes reproducible image review.

In a real-world data study conducted with the Institute of Pathology at Heidelberg University, the AI models identified up to 24% more artifacts missed by histotechnicians and reduced hands-on review time by 69%, enabling laboratories to reallocate skilled personnel to higher-value operational tasks.

Expanding Clinical Scanning Capabilities Across Laboratories

To accommodate diverse laboratory caseloads, Leica Biosystems is extending its clinical scanning systems. The high-throughput Aperio GT 450 DX clinical scanner, which features a 450-slide capacity and small operational footprint, now includes new manual scan capabilities for complex slides, advanced DICOM capabilities, and z-stacking functionality for clinical environments.

Additionally, the company has added the Aperio GT 180 DX clinical scanner to serve mid-volume laboratories. Featuring a 180-slide capacity alongside the same scanning speeds and core feature set as the GT 450 DX, the GT 180 DX assists laboratories in constructing streamlined clinical scanning procedures tailored to their specific operational needs and staffing models, furthering connected diagnostic workflows across institutions.

“Every improvement in the pathology workflow matters because patients and clinicians are waiting for answers that guide care,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “These FDA 510(k) clearances demonstrate Leica Biosystems’ leadership in advancing digital pathology beyond individual products toward connected, standardized workflows that help laboratories operate with greater confidence and consistency. By embedding AI-assisted quality control directly into the scanning workflow and expanding clinical scanning options, we are enabling laboratories to scale digital pathology in ways that support timely diagnosis, pathologist efficiency and better care for patients.”

As part of Danaher’s connected ecosystem of life sciences and diagnostics companies, Leica Biosystems supports nearly 2 million cancer tests globally each week, providing end-to-end solutions spanning from initial biopsy to final diagnosis.

Addressing Operational and Regulatory AI Demands

As healthcare systems accelerate technology transformation, managing the expansion of healthcare AI across clinical workflows and operational systems requires new oversight frameworks. Vitea’s platform equips Mercyhealth with centralized policy orchestration, continuous drift monitoring, and performance oversight tailored for complex multi-site clinical operations spanning northern Illinois and southern Wisconsin.

The system deploys over 100 out-of-the-box healthcare-specific policies that operate in real time across every prompt and response. This structure ensures that rapidly expanding technology initiatives protect patient safety and maintain data integrity across all care locations.

“At Mercyhealth, we’ve always held ourselves to a high bar when it comes to technology and security,” said Ali Olia, Chief Information Officer at Mercyhealth. “But AI introduces a new category of risk that traditional security tools simply weren’t built to address. These are non-deterministic systems — they don’t behave the same way twice — and that requires a fundamentally different approach to governance. Vitea gives us the infrastructure to stay ahead of that risk and continue innovating boldly.”

Strengthening Patient Safety and Oversight

Operating across multiple states with differing regulatory standards, Mercyhealth required a central infrastructure capable of maintaining unified compliance. The implementation of Vitea allows deviations in model behavior to be identified early in the clinical workflow, safeguarding data integrity and operational consistency.

“The moment AI touches patient care, the bar for data integrity and accountability goes up significantly,” said Jeremy Colson, Chief Data and Analytics Officer at Mercyhealth. “With Vitea, we have visibility into how our AI applications are performing and the ability to enforce policy across them, so deviations surface early rather than after the fact. For a health system at our scale, that level of oversight isn’t optional.”

Embedding Governance into Strategy

The partnership highlights an industry-wide evolution toward integrating a dedicated AI governance platform directly into core technology strategies, prioritizing long-term patient safety while advancing clinical efficiency.

Shantanu Nigam, CEO of Vitea, said, “Mercyhealth is building and adopting real AI capabilities, both through partners and in-house applications. They understand the risks and they are committed to doing this right for their patients, their staff, and their communities. We built Vitea for organizations like this: forward-thinking teams that want to move fast without leaving governance behind. We are proud to be their partner.”

Under the terms of the agreement, more than 1,300 pieces of medical technology will be integrated into Catholic Health’s hospitals and ambulatory centers. This modernization effort is targeted at several high-volume service lines, including cardiology, oncology, neurology, and women’s health. Approximately 50% of the planned equipment additions are scheduled to arrive within the first three years of the alliance. This phased rollout includes the installation of advanced MR, CT, and PET technologies equipped with on-device AI solutions, as well as hundreds of ultrasound systems. A unique element of the partnership involves an embedded cardiovascular scientist who will work directly with Catholic Health clinicians to ensure that technology innovation remains closely aligned with frontline patient care needs.

Financial and Operational Modernization

The Care Alliance partnership is structured to provide Catholic Health with significant capital savings compared to traditional equipment purchasing models. By utilizing unitary payments and accelerators, the system intends to reinvest saved resources into further technology modernization and the growth of clinical programs. Beyond simple hardware acquisition, the 10-year agreement includes a comprehensive multivendor service component. This ensures that GE HealthCare manages the maintenance, lifecycle, and fleet management for equipment across all 40+ sites, maximizing uptime and asset utilization. This transition from a traditional transactional model to a service-based alliance is designed to reduce the total cost of ownership while ensuring equipment reliability across the enterprise.

AI Integration and Digital Workflow Optimization

Artificial intelligence and cloud computing form the digital backbone of the new alliance, with a specific focus on easing the cognitive load on clinicians and reducing manual administrative tasks. One of the central digital solutions being implemented is Imaging 360, a cloud-based radiology operations platform. This system unifies radiology workflows and centralizes performance insights, allowing Catholic Health to manage imaging operations across multiple sites with greater consistency. The integration of AI-powered tools is also expected to streamline patient scheduling and monitoring, potentially decreasing the time from diagnostic imaging to the commencement of treatment.

For patients on Long Island, the partnership aims to expand access to specialized services closer to home. Upgraded capabilities in OB/GYN, maternal-infant care, and oncology diagnostics are expected to arrive at flagship locations such as St. Francis Hospital & Heart Center and Good Samaritan University Hospital within the first year. Gary Havican, Interim President and CEO of Catholic Health, noted that the partnership allows physicians to have a “meaningful voice in shaping the future of care,” ensuring that technological innovation is guided by real-world clinical insights. As the alliance progresses, Catholic Health will continue to scale these capabilities across Mercy Hospital, St. Joseph Hospital, St. Catherine of Siena Hospital, and its extensive network of ambulatory sites.

A significant component of the ongoing expansion involves the installation of digital door signs powered by hellocare.ai. These devices provide clinicians and staff with real-time access to critical patient data directly outside of rooms, facilitating better communication and streamlining internal workflows. The broader intelligent hospital room strategy is designed to create a more responsive environment by combining computer vision, workflow automation, and virtual monitoring. Jordan M. Tannenbaum, MD, MBA, MPH, chief information officer and chief medical information officer at Saint Peter’s Healthcare System, stated, “Our goal is to leverage technology in ways that meaningfully improve both the patient and clinician experience,” and added, “Through our partnership with hellocare.ai, we have implemented intelligent room technology and AI assisted workflows that improve patient safety, enhance communication, and support our care teams with more proactive interventions.”

The platform integrates virtual care delivery with AI-assisted observation to identify potential risks early and support clinical teams. Linda Carroll, MSN, RN, RN-BC, vice president of Patient Care Services and chief nursing officer at Saint Peter’s Healthcare System, noted, “Virtual nursing and AI assisted patient observation technologies are helping us transform the inpatient experience for both patients and staff,” and remarked, “The ability to proactively identify patient risks such as falls while also supporting nurses with virtual workflows has already demonstrated significant value for our teams and the patients we serve.” Labinot Bytyqi, Founder and CEO of hellocare.ai, expressed pride in the partnership, saying, “We are proud to partner with Saint Peter’s Healthcare System as they continue expanding their intelligent hospital room strategy,” and concluded, “Saint Peter’s has embraced innovation in a thoughtful and impactful way by combining AI assisted safety technologies, virtual care delivery, and real time clinical communication tools to create a safer and more connected patient care environment.”

The company currently provides services to more than 1.1 million individuals and has demonstrated significant operating leverage by scaling its operations with limited headcount growth. This partnership is expected to yield mutual strategic advantages, as Prosus intends to support the scaling of the consumer ecosystem and facilitate expansion into large international territories where Prosus maintains a strong presence. Furthermore, the collaboration will accelerate AI-led product development, granting Alan access to the Prosus Large Commerce Model (LCM). This move aligns with the life assistant strategy of the investor, aiming to broaden its reach within the healthcare domain. The completion of the Prosus Alan investment remains contingent upon receiving necessary regulatory approvals, including those required by the relevant financial authorities in France.

Executive Perspectives on the Partnership

“Healthcare presents one of the most significant global opportunities for AI-led transformation,” stated Fahd Beg, Head of Investments at Prosus Group. “Alan has built something unique: an integrated platform where insurance, prevention and care delivery reinforce each other, creating an exceptional healthcare experience for consumers and outstanding platform engagement. We’re excited to partner with Alan to accelerate its international expansion and unlock value through our ecosystem.”

Jean-Charles Samuelian-Werve, Co-founder and CEO of Alan, emphasized the urgency of modernizing medical access: “Health can’t wait, not for symptoms to get worse, not for a six-month appointment, not for the system to catch up. Yet that is exactly how healthcare works today. We believe great health is a universal right, and that prevention should be too. For ten years we have shown that technology can turn healthcare from reactive to proactive, helping people act early instead of reacting late. That is what prevention insurance is, and it’s the category we are building. We selected Prosus for their very deep expertise in international expansion and consumer products and to benefit from the incredible ecosystem they are building. We are still at the very beginning of what Alan can become.” As the company moves forward, it will continue to manage its consumer ecosystem and life assistant strategy to maintain its market position while awaiting final clearance from financial authorities. The firm’s ability to maintain headcount growth at a controlled rate while utilizing primary and secondary equity for expansion remains a core component of its operational model.

Cadence’s Clinical Intelligence platform is designed to identify patient risks early while supporting older adults between clinical visits through daily vital monitoring, medication adjustment assistance and personalized lifestyle coaching. The platform integrates directly with partner health systems, medical groups, electronic medical records (EMRs) and existing clinical workflows, where supervised AI agents monitor patient health and assist care teams with timely interventions. Founder and CEO Chris Altcheck said the platform was built to “solve the clinical labor constraint at the heart of the chronic disease crisis.” He further stated, “Our AI automates care under close supervision, guided by our medical group, governed by our health system clinical protocols, and reimbursed through billing infrastructure and at-risk contracts. We’re treating 100,000 patients with that system today, alongside partners committed to changing the status quo in chronic care. This investment builds the infrastructure to treat millions.”

The company currently collaborates with more than 20 health systems and provides care for over 100,000 active patients. According to company executives, Cadence tripled annual recurring revenue during 2025 while helping save Medicare approximately $2.7 million each week. Alongside the funding announcement, the company revealed new affiliations with Duke Health and Texas Health Resources. Jeffrey Ferranti, M.D., senior vice president and chief digital officer of Duke Health, said, “At Duke Health, our mission is to advance the health of our patients and the communities we serve. The moments that matter most for a patient’s health often happen at home, not in the clinic. With Cadence, we stay connected to patients with chronic conditions around the clock, monitoring their health continuously so we can intervene early and keep them healthy. Together, we’re reimagining what care can be: healthier patients and a stronger, more affordable health system for all.” Cadence also highlighted peer-reviewed evidence supporting its platform, including a Mayo Clinic study reporting a 27% reduction in hospital admissions and a $1,302 annual reduction in total care costs per patient, while research published in the Journal of the American College of Cardiology found its remote patient care hypertension program achieved a 70% improvement in blood pressure control. These findings reinforce the company’s approach to AI chronic care.

The new offering builds on Helix, a product DeepIntent introduced in March that opened the data infrastructure supporting its own solutions to agencies such as Deerfield, Eversana, Klick Health and Trinity. Through Helix AI, marketers can interact with a database covering 4 million healthcare providers and 250 million patient lives. The technology is intended to streamline activities including audience sizing, prescriber overlap analysis and campaign performance measurement by reducing reliance on traditional database workflows.

Industry users say the technology can significantly reduce the time required for complex analysis. “Helix AI provides a strategic edge by putting advanced, purpose-built data capabilities directly into the hands of our strategists,” Liz Mansell, senior vice president, media strategy at Fingerpaint Marketing, said in a statement. “Analysis that once took days, and often wasn’t feasible at this depth, now takes minutes.” Agencies are also able to tailor the platform with their own first-party analytics, media assets and data sources. Supporters of the underlying Helix platform have highlighted efficiency gains, with Paul Cross, vice president, data strategy and reporting at Deerfield, stating in a DeepIntent video that workflows became 50% faster. Cross also said the platform transformed data management by bringing together information that had previously been spread across multiple systems.

The launch follows a period of significant activity for DeepIntent. Earlier this year, the company secured $637 million from Vitruvian Partners. Founded in 2016, DeepIntent was acquired by Propel Media in 2017 and later became the target of a buyout proposal from IQVIA in 2022, although that transaction was not completed after facing opposition from the Federal Trade Commission. Meanwhile, IQVIA has continued expanding its own AI portfolio, unveiling technology this week aimed at helping pharmaceutical marketers identify nurse practitioners and physician assistants who write prescriptions.

The agreement underscores a shared commitment between the two organizations to address evolving healthcare challenges through technology-driven innovation. By combining their respective expertise and resources, Kaopiz Holdings and QuantumTX aim to create AI healthcare solutions that enhance disease prevention and patient outcomes. The collaboration encompasses the integration of IoT engineering capabilities with advanced analytics to build comprehensive health data ecosystems capable of supporting preventive care initiatives.

The partnership’s scope includes the development of AI healthcare solutions designed to deliver actionable insights for preventive medical interventions. Through the deployment of IoT-enabled monitoring systems and intelligent data processing frameworks, the organizations seek to establish next-generation platforms that can identify health risks before they escalate into serious conditions. This approach represents a meaningful shift toward proactive rather than reactive healthcare delivery models.

The MOU establishes a foundation for collaborative research, product development, and market implementation of these technologies. Both entities recognize the growing demand for intelligent healthcare infrastructure capable of processing vast quantities of health information in real-time. By pooling technical expertise in artificial intelligence, IoT engineering, and health data analytics, the partnership positions itself to deliver solutions with practical applications across multiple healthcare settings and patient demographics.

The initiative reflects broader industry trends toward digitalization and intelligent health management systems. The integration of AI-powered healthcare solutions with IoT infrastructure creates opportunities for continuous patient monitoring, early warning systems, and personalized preventive care recommendations. Through this strategic collaboration, Kaopiz Holdings and QuantumTX aim to contribute meaningfully to the advancement of preventive healthcare technology and improved health outcomes globally.